Innovative financing instruments for global health 2002–15: a systematic analysis

Rifat Atun, Sachin Silva, Felicia Knaul

Research output: Contribution to journalComment/debate

13 Citations (Scopus)

Abstract

Development assistance for health (DAH), the value of which peaked in 2013 and fell in 2015, is unlikely to rise substantially in the near future, increasing reliance on domestic and innovative financing sources to sustain health programmes in low-income and middle-income countries. We examined innovative financing instruments (IFIs)—financing schemes that generate and mobilise funds—to estimate the quantum of financing mobilised from 2002 to 2015. We identified ten IFIs, which mobilised US$8·9 billion (2·3% of overall DAH) in 2002–15. The funds generated by IFIs were channelled mostly through GAVI and the Global Fund, and used for programmes for new and underused vaccines, HIV/AIDS, malaria, tuberculosis, and maternal and child health. Vaccination programmes received the largest amount of funding ($2·6 billion), followed by HIV/AIDS ($1080·7 million) and malaria ($1028·9 million), with no discernible funding targeted to non-communicable diseases.

Original languageEnglish (US)
Pages (from-to)e720-e726
JournalThe Lancet Global Health
Volume5
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

AIDS Vaccines
Malaria
Health
Financial Management
Vaccination
Acquired Immunodeficiency Syndrome
Tuberculosis
HIV
Global Health
Maternal Health
Child Health

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Innovative financing instruments for global health 2002–15 : a systematic analysis. / Atun, Rifat; Silva, Sachin; Knaul, Felicia.

In: The Lancet Global Health, Vol. 5, No. 7, 01.07.2017, p. e720-e726.

Research output: Contribution to journalComment/debate

@article{8fa52f4d52a347fd8c2d7fb3b5be2ee3,
title = "Innovative financing instruments for global health 2002–15: a systematic analysis",
abstract = "Development assistance for health (DAH), the value of which peaked in 2013 and fell in 2015, is unlikely to rise substantially in the near future, increasing reliance on domestic and innovative financing sources to sustain health programmes in low-income and middle-income countries. We examined innovative financing instruments (IFIs)—financing schemes that generate and mobilise funds—to estimate the quantum of financing mobilised from 2002 to 2015. We identified ten IFIs, which mobilised US$8·9 billion (2·3{\%} of overall DAH) in 2002–15. The funds generated by IFIs were channelled mostly through GAVI and the Global Fund, and used for programmes for new and underused vaccines, HIV/AIDS, malaria, tuberculosis, and maternal and child health. Vaccination programmes received the largest amount of funding ($2·6 billion), followed by HIV/AIDS ($1080·7 million) and malaria ($1028·9 million), with no discernible funding targeted to non-communicable diseases.",
author = "Rifat Atun and Sachin Silva and Felicia Knaul",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/S2214-109X(17)30198-5",
language = "English (US)",
volume = "5",
pages = "e720--e726",
journal = "The Lancet Global Health",
issn = "2214-109X",
publisher = "Elsevier BV",
number = "7",

}

TY - JOUR

T1 - Innovative financing instruments for global health 2002–15

T2 - a systematic analysis

AU - Atun, Rifat

AU - Silva, Sachin

AU - Knaul, Felicia

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Development assistance for health (DAH), the value of which peaked in 2013 and fell in 2015, is unlikely to rise substantially in the near future, increasing reliance on domestic and innovative financing sources to sustain health programmes in low-income and middle-income countries. We examined innovative financing instruments (IFIs)—financing schemes that generate and mobilise funds—to estimate the quantum of financing mobilised from 2002 to 2015. We identified ten IFIs, which mobilised US$8·9 billion (2·3% of overall DAH) in 2002–15. The funds generated by IFIs were channelled mostly through GAVI and the Global Fund, and used for programmes for new and underused vaccines, HIV/AIDS, malaria, tuberculosis, and maternal and child health. Vaccination programmes received the largest amount of funding ($2·6 billion), followed by HIV/AIDS ($1080·7 million) and malaria ($1028·9 million), with no discernible funding targeted to non-communicable diseases.

AB - Development assistance for health (DAH), the value of which peaked in 2013 and fell in 2015, is unlikely to rise substantially in the near future, increasing reliance on domestic and innovative financing sources to sustain health programmes in low-income and middle-income countries. We examined innovative financing instruments (IFIs)—financing schemes that generate and mobilise funds—to estimate the quantum of financing mobilised from 2002 to 2015. We identified ten IFIs, which mobilised US$8·9 billion (2·3% of overall DAH) in 2002–15. The funds generated by IFIs were channelled mostly through GAVI and the Global Fund, and used for programmes for new and underused vaccines, HIV/AIDS, malaria, tuberculosis, and maternal and child health. Vaccination programmes received the largest amount of funding ($2·6 billion), followed by HIV/AIDS ($1080·7 million) and malaria ($1028·9 million), with no discernible funding targeted to non-communicable diseases.

UR - http://www.scopus.com/inward/record.url?scp=85020385123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020385123&partnerID=8YFLogxK

U2 - 10.1016/S2214-109X(17)30198-5

DO - 10.1016/S2214-109X(17)30198-5

M3 - Comment/debate

C2 - 28619230

AN - SCOPUS:85020385123

VL - 5

SP - e720-e726

JO - The Lancet Global Health

JF - The Lancet Global Health

SN - 2214-109X

IS - 7

ER -